Story perspectives

Novo Nordisk Restructures: 9,000 Jobs Cut, New Leadership

1/5/2026

Summary

Story summary

Jennifer Duck, U.S. public affairs head at Novo Nordisk, has left the company amid a restructuring that cuts 9,000 jobs.
Chris Pernie will replace Duck on an interim basis as Novo Nordisk reorganizes its U.S. public affairs.
Restructuring comes as U.S. President Donald Trump pressures drug pricing and Eli Lilly competes in weight loss, while Novo Nordisk launches a Wegovy pill and CEO Mike Doustdar seeks to restore investor confidence after a tough year.

History

Historical Context

The Drug Pricing Reform Act, enacted in 2020, aimed to reduce prescription drug costs in the U.S. Amidst this regulatory pressure, Novo Nordisk announced a significant layoff of 9,000 employees to streamline operations. This restructuring highlights ongoing challenges in the pharmaceutical industry, where companies like Novo Nordisk and Eli Lilly face scrutiny over drug pricing and innovation strategies.

1 of 2

Story summary

Jennifer Duck, U.S. public affairs head at Novo Nordisk, has left the company amid a restructuring that cuts 9,000 jobs.
Chris Pernie will replace Duck on an interim basis as Novo Nordisk reorganizes its U.S. public affairs.
Restructuring comes as U.S. President Donald Trump pressures drug pricing and Eli Lilly competes in weight loss, while Novo Nordisk launches a Wegovy pill and CEO Mike Doustdar seeks to restore investor confidence after a tough year.

1 / 2